A biopharmaceutical company focused on developing and commercializing medicines for rare, autoimmune, and severe inflammatory diseases. Horizon Therapeutics is known for its flagship products like Tepezza for thyroid eye disease and Krystexxa for chronic refractory gout, making it a key player in specialty pharmaceuticals.
7 members of Congress have disclosed 16 trades in Horizon Therapeutics Public Limited Company (HZNP), a Healthcare company. The buy/sell breakdown shows 9 purchases versus 7 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2023-02-03 | Greg Landsman | sell | $1K – $15K |
| 2023-02-01 | Greg Landsman | sell | $1K – $15K |
| 2023-01-31 | Daniel Goldman | sell | $15K – $50K |
| 2023-01-18 | Greg Landsman | buy | $1K – $15K |
| 2022-11-03 | Rohit Khanna | sell | $1K – $15K |
| 2022-05-04 | MICHAEL T. MCCAUL | sell | $1K – $15K |
| 2021-01-13 | MICHAEL T. MCCAUL | buy | $15K – $50K |
| 2020-12-14 | MICHAEL T. MCCAUL | buy | $1K – $15K |
| 2018-11-21 | MICHAEL T. MCCAUL | buy | $1K – $15K |
| 2018-05-31 | JAMES B. RENACCI | buy | $1K – $15K |
| 2017-06-06 | Kurt Schrader | buy | $1K – $15K |
| 2016-02-19 | MICHAEL T. MCCAUL | buy | $1K – $15K |
| 2015-08-27 | MICHAEL T. MCCAUL | buy | $1K – $15K |
| 2015-08-07 | JAMES B. RENACCI | sell | $1K – $15K |
| 2015-05-27 | Thomas MacArthur | sell | $1K – $15K |
| 2015-05-26 | Thomas MacArthur | buy | $1K – $15K |